Inhibition of hydroxycinnamic acid sulfation by flavonoids and their conjugated metabolites by Wong, CC & Williamson, G
promoting access to White Rose research papers 
   
White Rose Research Online 
eprints@whiterose.ac.uk 
 
 
 
Universities of Leeds, Sheffield and York 
http://eprints.whiterose.ac.uk/ 
 
 
 
This is an author produced version of a paper published in BioFactors. 
White Rose Research Online URL for this paper: 
 
http://eprints.whiterose.ac.uk/78309/ 
 
 
 
Paper: 
Wong, CC and Williamson, G (2013) Inhibition of hydroxycinnamic acid sulfation 
by flavonoids and their conjugated metabolites. BioFactors, 39 (6). 644 – 651. 
 
http://dx.doi.org/10.1002/biof.1127 
 
 
1 
 
Inhibition of hydroxycinnamic acid sulfation by flavonoids and their 
conjugated metabolites 
 
 
Chi Chun Wong
 
and Gary Williamson 
 
School of Food Science and Nutrition, University of Leeds, Leeds LS2 9JT, UK 
 
 
 
Correspondence to: Professor Gary Williamson, School of Food Science and Nutrition, 
University of Leeds, Leeds, LS2 9JT, UK.  
Tel: +44 (0) 113 343 8380 
Fax: +44 (0) 113 343 2982 
Email: g.williamson@leeds.ac.uk 
 
 
2 
 
Abstract.  
Hydroxycinnamic acids and flavonoids are dietary phenolic antioxidants that are 
abundant in our diet. Hydroxycinnamic acids are highly sulfated in vivo, and sulfotransferases 
(SULTs), in particular SULT1A1, play a major role in their metabolism. Flavonoids are potent 
inhibitors of human SULTs. In this study, the potential metabolic interaction between dietary 
hydroxycinnamic acids and flavonoids was investigated. Flavonoids, such as luteolin, 
quercetin, daidzein and genistein, are identified as potent inhibitors of hydroxycinnamic acid 
sulfation in human liver S9 homogenate with IC50 values less than 1 μM. The inhibitory 
activity was less potent in the human intestinal S9 homogenate. We also demonstrate that 
quercetin conjugates found in vivo (quercetin-3-O-glucuronide, quercetin-7-O-glucuronide, 
and quercetin-3′-O-sulfate) moderately inhibited the sulfation of hydroxycinnamic acids in 
human liver S9. In an intact cellular system, human HepG2 cells, caffeic acid and ferulic acid 
sulfation was inhibited by luteolin and quercetin (IC50: 1.6-3.9 μM). Quercetin-3′-O-sulfate 
weakly inhibited sulfation. Quercetin glucuronides, limited by their low cellular uptake, were 
ineffective. These data suggest that the inhibition of SULTs by flavonoids and in vivo 
flavonoid conjugates may modify the bioavailability of dietary hydroxycinnamic acids by 
suppressing their conversion to sulfated metabolites.  
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1. Introduction 
In humans, the first-pass metabolism of hydroxycinnamic acids plays a major role in 
limiting their bioavailability. Human studies and in vitro mechanistic studies showed that 
hydroxycinnamic acids are predominantly sulfated in the intestine and liver [1-6]. 
Characterization with recombinant human SULTs demonstrated that SULT1A1 and SULT1E1 
are the major isoforms involved in the sulfation of hydroxycinnamic acids [4]. SULT1A1, 
highly expressed in both human liver and intestine, is the most active in the sulfation of all the 
major hydroxycinnamic acids found in the diet. SULT1E1 catalyzes the sulfation of the 
4-hydroxyl groups of ferulic and dihydroferulic acids. Therefore, inhibition of SULTs may be a 
possible strategy to increase the proportion of unconjugated hydroxycinnamic acids, which, in 
turn, could lead to a modified or even enhanced bioefficacy [7]. 
Flavonoids are natural inhibitors of SULTs. Quercetin, the most abundant flavonol in 
foods, is a potent inhibitor of SULT1A1 with IC50 value of <100 nM [8-10]. Flavonoids from 
different subgroups including flavones, flavonols, flavanone and isoflavones also show highly 
effective inhibition of SULTs, especially SULT1A1. Given the importance of SULT1A1 in the 
sulfation of hydroxycinnamic acids, the concomitant consumption of flavonoids and 
hydroxycinnamic acids may inhibit the metabolism of the latter. In particular, human intestinal 
SULTs may be inhibited by dietary doses of flavonoids, since the local concentrations of 
flavonoids in the gut is much higher than that in plasma [11]. Human liver is another important 
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site of hydroxycinnamic acid sulfation. However, flavonoids are extensively metabolized in 
vivo into conjugates that are present in much lower concentrations in the circulation (<10 µM). 
It is thus critical to evaluate the inhibitory effect, if any, of the biologically relevant flavonoid 
conjugates on the sulfation of hydroxycinnamic acids.  
In this study, we investigated the inhibitory effects of flavonoids and their conjugates on 
the sulfation of five major dietary hydroxycinnamic acids (caffeic acid, dihydrocaffeic acid, 
dihydroferulic acid, ferulic acid and isoferulic acids) using human intestine and liver 
homogenates. Furthermore, we examined the inhibitory effect of luteolin, quercetin and 
quercetin conjugates (gluucronides and sulfate) on hydroxycinnamic acid sulfation in the 
human hepatoma cell line, HepG2, as a model for human liver metabolism.  
 
2. Methods and materials 
 
2.1. Chemicals 
Caffeic acid, ferulic acid, isoferulic acid, quercetin, (+)-catechin and (-)-epicatechin were 
purchased from Sigma-Aldrich (St. Louis, MO). Apigenin, daidzein, eriodictyol, genistein, 
hesperetin, kaempferol, isorhamnetin, luteolin and phloretin were obtained from 
Extrasynthèse, (Genay, France). Dihydrocaffeic acid and dihydroferulic acid were purchased 
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from Alfa Aesar (Lancashire, UK). The conjugates caffeic acid-3-O-glucuronide, caffeic 
acid-4-O-glucuronide, caffeic acid-3-O-sulfate, caffeic acid-4-O-sulfate, dihydroferulic 
acid-4-O-sulfate, ferulic acid-4-O-glucuronide, ferulic acid-4-O-sulfate, isoferulic 
acid-3-O-glucuronide, isoferulic acid-3-O-sulfate were synthesized as described elsewhere 
[12] and kindly provided by Prof Denis Barron, Nestle Research Center, Lausanne, 
Switzerland. Quercetin-7-O-glucuronide and quercetin-3-O-glucuronide were synthesized 
enzymatically and purified by HPLC [13, 14]; quercetin-3′-O-sulfate was chemically 
synthesized as described [15, 16]. Identity of the compounds was further confirmed by 
comparing the retention time and absorption spectra of the authentic standards kindly provided 
by Dr. Paul Kroon and Dr Paul Needs. The purities were checked by HPLC to be over 95 %. 
3'-phosphoadenosine-5'-phosphosulfate (PAPS) was from MP Biochemicals (London, UK). 
Pooled Liver S9 homogenate was purchased from Sigma-Aldrich, while pooled intestinal 
(duodenum/jejunum) S9 homogenate was from Xenotech (Lenexa, Kansas). All other 
chemicals, unless otherwise stated, were purchased from Sigma-Aldrich.  
 
2.2. Inhibition of hydroxycinnamic acid sulfation by flavonoids in human liver and intestinal 
S9  
The incubation mixture, in a final volume of 50 μL, consisted of 100 mM potassium 
phosphate buffer (pH 7.4), with 100 µM vitamin C, 100 µM PAPS and 1 mM DTT. Human 
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liver S9 and intestinal S9 homogenates were used at 1 mg/mL and 0.4 mg/mL, respectively. 
The flavonoids were added from a 5 mM stock solution dissolved in DMSO, with final DMSO 
concentration equalized to 0.2 %. Quercetin-3-O-glucuronide, quercetin-7-O-glucuronide and 
quercetin-3′-O-sulfate were dissolved in water. After a 15 min pre-incubation period, the 
reaction was initiated by adding 10 µM cinnamic acids and 25 µM dihydrocinnamic acids from 
a 50 mM stock solution in DMSO. To inhibit hydrolysis of quercetin glucuronides, 5 mM 
saccharolactone was added. After 30 min incubation in a 37 
0
C water bath, the reaction was 
stopped by the addition of 10 μL ice-cold acetonitrile containing 500 mM HCl. Controls were 
treated under identical conditions and consisted of samples with 0.2 % DMSO (final 
concentration) added to the buffer. Samples were stored at -70 
0
C until analysis. Due to the 
co-elution of dihydrocaffeic acid sulfates with unknown components in the S9 homogenates, 
an extraction procedure was necessary only for samples from dihydrocaffeic acid. After 
stopping the reaction, the buffer was evaporated in vacuo. Residue was extracted first with 60 
µL of methanol, and then with 60 µL of acetonitrile. The supernatants of the extracts were 
combined and evaporated to dryness. Finally, the extracted material was re-suspended in 60 µL 
of the initial mobile phase and analyzed by HPLC. Extraction efficiency was 92 ± 4 % for 
dihydrocaffeic acid conjugates (n=3).  
 
2.3. Hydrolysis of flavonoids conjugates in human liver S9  
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Quercetin-3-O-glucuronide, quercetin-7-O-glucuronide, and quercetin-3′-O-sulfate, at 
20 µM, were added to 100 mM potassium phosphate buffer (pH 7.4), with 100 µM vitamin C, 
1 mM DTT and 1 mg/mL liver S9 homogenates, in a final volume of 50 µL. After 30 min 
incubation at 37 
0
C, the reaction was stopped by the addition of 10 μL ice-cold acetonitrile 
containing 500 mM HCl.  
 
2.5. HepG2 cell culture and metabolism 
HepG2 cells (ATCC) were routinely cultured in 75 cm
2
 cell culture flasks (Corning 
Costar Corp., Cambridge, MA) at 37 
0
C under a humidified 5 % CO2 / O2 atmosphere. The 
culture media consisted of Eagle's Minimum Essential Medium media (ATCC) supplemented 
with 10% fetal bovine serum and 100 U/ml penicillin- streptomycin. All experiments were 
performed with HepG2 cells between passages 80 to 95. For metabolic studies, HepG2 cells 
were seeded into 12-well plates (Corning Costar Corp., Cambridge, MA) at a cell density of 2 x 
10
5
 per well. The cell monolayers were allowed to grow over 96 h before they were used for 
experiments. Hydroxycinnamic acid metabolism experiments were carried out in serum-free 
media with 100 µM vitamin C and 1.8 mM CaCl2, adjusted to pH 7. Caffeic acid and ferulic 
acid (10 µM) were added from a 50 mM stock solution in DMSO. Quercetin and luteolin (5 
mM) were also dissolved in DMSO and added to the media to give a final DMSO concentration 
of 0.25 %. 0.4 mL of hydroxycinnamic acids, with or without the inhibitors, were added to the 
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HepG2 cells and incubated for 4 h at 37 
0
C. The incubation media were then collected, 
acidified with 1 mM vitamin C and dried under vacuum. The residue was extracted by 
sonication for 5 min and vortex for 1 min, first with 500 µL acetonitrile, followed by 500 µL 
methanol. The extracts were combined and evaporated under vacuum. Prior to HPLC analysis, 
the dried residue was re-dissolved in 100 µL of initial mobile phase.  
 
2.6. Uptake of quercetin metabolites into HepG2 cells.   
For the uptake study, HepG2 cells were seeded into 12-well plates (Corning Costar Corp., 
Cambridge, MA) at a cell density of 2 x 10
5
 per well. The cell monolayers were allowed to 
grow over 96 h before they were used for uptake experiments. Uptake experiments were 
carried out using serum-free media with 100 µM vitamin C and 1.8 mM CaCl2, adjusted to pH 
7. After removal of media, the cells were washed twice with 0.4 mL transport buffer and 
incubated for 10 min. Preincubation buffer was aspirated and replaced with 0.4 mL transport 
buffer containing quercetin metabolites. After 4 h, 2 mL ice-cold transport buffer containing 
0.2 % bovine serum albumin (BSA) was added. This was quickly aspirated and further washed 
t 
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wice with 0.5 mL ice-cold transport buffer with 0.2 % BSA. Finally, the cells were rinsed 
with 0.5 mL ice-cold transport buffer without BSA. Cells were collected with 0.4 mL 50 % 
methanol and stored at -80 
0
C. Extraction was performed by sonication for 5 min followed by 
the addition of 1 mL of ice-cold acetone. The samples were placed in a -20 
0
C freezer for 1 h 
and centrifuged at 17,000 g for 5 min. The supernatant was collected and evaporated to dryness 
in vacuo at 30 
0
C and stored at -20 
0
C until analysis. The protein pellet was re-dissolved in 0.1 
N NaOH and the protein contents were determined by the Bradford assay. All the uptake values 
were corrected against protein content.  
 
2.7. HPLC methodology  
HPLC analyses were carried out using the Agilent 1200 series liquid chromatography 
system. For the analysis of caffeic acid, ferulic acid, isoferulic acid, dihydroferulic acid and 
their conjugates, chromatography was performed with a Zorbax XDB-C18 column (4.6 x 150 
mm, 5 μm). The mobile phase consisted of 20 mM ammonium formate, pH 2.8 (A) and 
methanol (B). For the analysis of caffeic acid and conjugates, samples were eluted at 1 mL/min 
with 5 % to 25 % B in 20 min, followed by 80 % B in 2 min and back to 5 % B for 3 min. For 
the analysis of ferulic and isoferulic acid and their conjugates, the gradient was from 10 % to 20 
% B in 10 min, to 60% B in 15 min, then set at 80 % B for 2 min and back to 10 % B for 3 min, 
at 1 mL/min. Dihydroferulic acid and conjugate analysis was carried out at 1 mL/min, from 10 
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% to 20 % B in 15 min, to 60 % B in 10 min, up to 80 % B for 2 min and finally to 10 % B for 
3 min. For dihydrocaffeic acid and conjugates, the analyses were performed with a Zorbax 
XDB-C18 column (4.6 x 50 mm, 1.8 μm) with 20 mM ammonium formate, pH 4.5 (A) and 
methanol (B) as the mobile phase. The gradient started at 3 % (B) kept for 15 min, followed by 
an increase to 40 % B in 5 min, and then returned to 3 % B for 5 min. Samples were centrifuged 
and 25 µL of the supernatant were injected into the column. UV-detection carried out at 280 
nm and 310 nm using a photodiode array detector. Caffeic, ferulic and isoferulic acids were 
quantified at 310 nm, dihydroferulic acid and dihydrocaffeic acid at 280 nm. The on-column 
limits of quantification of this HPLC method for the quantification of caffeic acid, ferulic acid 
and isoferulic acid were ~1 pmol, and ~5 pmol for dihydrocaffeic acid and dihydroferulic acid. 
All conjugates were positively identified by comparing the retention times and UV absorption 
spectra with those of the authentic synthetic standards. Conjugates were quantified using 
calibration curves of the authentic standards of glucuronides and sulfates. Standard curves 
were linear over the range loaded (0.1 to 2 nmol, R
2
 > 0.99). Slope of peak area (AU) / amount 
(nmol): caffeic acid-3-O-sulfate: 1120; caffeic acid-4-O-sulfate: 512; dihydrocaffeic 
acid-3-O-sulfate: 113; dihydroferulic acid-4-O-sulfate: 157; ferulic acid-4-O-sulfate: 922; 
isoferulic acid-3-O-sulfate: 872 (corrected for purity). For quercetin conjugates, analyses were 
performed with a Zorbax XDB-C18 column (4.6 x 50 mm, 1.8 μm) with 20 mM ammonium 
formate, pH 4.5 (A) and methanol (B) as the mobile phase. Elution was performed at 1 mL/min 
12 
 
and the gradient started at 30 % (B) and increased linearly to 50 % in 10 min, and equilibrated 
at 30 % for 2.5 min. The limit of detection for the quantification of quercetin was 0.02 µM. 
Quantification was based on the peak area at 370 nm. 
 
2.8. Data analysis 
Data are shown as mean ± S.D. Statistical differences were determined using analysis of 
variance using the student’s t-test. Differences were considered significant when p<0.05. 
 
3. Results 
 
3.1. Inhibition of hydroxycinnamic acid sulfation by flavonoids in human intestinal S9 
The inhibitory effect of 11 flavonoids on hydroxycinnamic acid sulfation was evaluated 
using human intestinal S9; caffeic acid and ferulic acid were chosen as representative 
substrates for SULT1A1 and SULT1E1, respectively. It was found that flavonoids inhibited 
the sulfation of caffeic acid and ferulic acid in a concentration-dependant manner. At 10 µM, 
all flavonoids, with the exception of epicatechin, inhibited sulfation of both caffeic acid and 
ferulic acid by >50 %. IC50 values are shown in Table 1. Sulfation of caffeic acid appeared to be 
more susceptible to inhibition, as indicated by lower IC50 values. Isoflavones genistein and 
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daidzein were the most potent inhibitors in the human intestinal S9, and they inhibited the 
sulfation of caffeic acid and ferulic acid with IC50 values of < 1 µM and 1.5-2.3 µM, 
respectively. Other good inhibitors included the flavones apigenin and luteolin, as well as 
phloretin, but for the flavanols, catechin and epicatechin, the inhibitory effect was relatively 
moderate. The inhibitory effect of isoflavones genistein and daidzein on dihydrocaffeic acid, 
dihydroferulic acid and isoferulic acid sulfation was further examined (Figure 1). Isoflavones 
were found to be potent inhibitors of caffeic and dihydrocaffeic acid sulfation, while they are 
less effective in inhibiting sulfation of methylated forms, in particular dihydroferulic acid.  
 
3.2. Inhibition of hydroxycinnamic acid sulfation by flavonoids in human liver S9 
Sulfation of caffeic acid and ferulic acid in liver S9 was more sensitive to inhibition by 
flavonoids. Inhibitory activities of the flavonoids are shown in Table 2. The most potent 
inhibitors were luteolin and quercetin. Luteolin, in particular, was found to strongly inhibit 
caffeic acid sulfation with IC50 = 0.08 µM. Quercetin, on the other hand, inhibited sulfation of 
caffeic acid and ferulic acid with IC50 values of 0.41 and 0.64 µM, respectively. Isoflavones 
genistein and daidzein were also potent inhibitors (IC50 < 1 µM), while catechin, epicatechin 
and hesperetin were weak inhibitors. The inhibitory activity of luteolin and quercetin was 
further evaluated with isoferulic acid, dihydrocaffeic acid and dihydroferulic acid (Figure 2). 
Luteolin was a highly effective sulfation inhibitor for all the hydroxycinnamic acids, with > 50 
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% inhibition at 1 µM. Sulfation of dihydrocaffeic acid and dihydroferulic acid were less 
strongly inhibited compared to their cinnamic acid counterparts. 
 
3.3. Inhibition of hydroxycinnamic acid by quercetin conjugates in liver S9 
Next, we evaluated the inhibitory effect of in vivo quercetin conjugates, 
quercetin-3-O-glucuronide, quercetin-7-O-glucuronide and quercetin-3′-O-sulfate, towards the 
sulfation of caffeic acid and ferulic acid in human liver S9. These conjugates significantly 
inhibited sulfation of caffeic acid and ferulic acid, albeit with IC50 values 1-2 orders of 
magnitude higher than that of the quercetin aglycone (Table 3). The overall potency of 
inhibition was in the order of quercetin-3′-O-sulfate > quercetin-7-O-glucuronide > 
quercetin-3-O-glucuronide. The human liver contained β-glucuronidase and sulfatase that may 
hydrolyze conjugates to quercetin, which in turn inhibits SULTs. We examined the hydrolysis 
of quercetin conjugates (20 µM) in human liver S9 homogenates and found that 
quercetin-3-O-glucuronide and quercetin-7-O-glucuronide were hydrolyzed significantly (27.2 
and 26.1 pmol / min per mg, respectively), whereas the hydrolysis of quercetin-3′-O-sulfate 
was slower (9.0 pmol / min per mg). To evaluate the potential role of hydrolysis by 
β-glucuronidase in the sulfation inhibitory activity of quercetin-3-O-glucuronide and 
quercetin-7-O-glucuronide, they were incubated with in the presence of saccharolactone, a 
β-glucuronidase inhibitor. HPLC analysis showed that saccharolactone completely inhibited 
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glucuronide hydrolysis. Inhibition of hydrolysis resulted in a marked reduction of the ability of 
quercetin-3-O-glucuronide and quercetin-7-O-glucuronide (20 µM) to inhibit the sulfation of 
caffeic acid (Figure 3). In particular, the inhibitory activity of quercetin-3-O-glucuronide was 
reduced from > 90% to only 20 %, and less than 50 % inhibition was observed at 50 µM. 
Quercetin-7-O-glucuronide maintained over 50 % inhibition at 20 µM, with IC50 value of 17.6 
µM. Hydrolysis of glucuronide conjugates thus plays an important role in their sulfation 
inhibitory activity.  
 
3.4. Metabolism of hydroxycinnamic acids in HepG2 cells and inhibition of sulfation by 
quercetin and conjugates 
Although flavonoids and their conjugates inhibited sulfotransferase activity in the 
cell-free preparations in vitro, their inhibition in intact cells may be limited by their access to 
the enzyme [8]. Thus, the inhibitory activity of flavonoids was further examined in human 
HepG2 cells. We first investigated the nature of metabolites of hydroxycinnamic acids 
produced by HepG2 cells. Caffeic and ferulic acids (10 µM) were separately incubated with the 
HepG2 cells for 4 h, and the media was analyzed by HPLC-UV. Sulfated metabolites were the 
major metabolites identified, while glucuronides were not formed to a significant extent. This 
is in good agreement with the metabolic profile found in in vitro incubations with human liver 
S9. For caffeic acid, we found that there was also significant methylation to form ferulic acid. 
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Next, the effect of flavonoids and their conjugates on hydroxycinnamic acid metabolism by 
HepG2 cells was investigated.  
As shown in Figure 4, quercetin and luteolin were potent inhibitors of sulfation in the 
HepG2 cells. Luteolin and quercetin significantly inhibited caffeic acid sulfation at 1 µM, with 
IC50 values of 1.6 and 1.9 µM respectively; they also inhibited ferulic acid sulfation with IC50 
values of 3.9 and 3.6 µM, respectively. On the other hand, the tested quercetin metabolites 
were weak inhibitors of sulfation. Among the quercetin conjugates, only quercetin-3′-O-sulfate 
showed significant inhibition of sulfation with IC50 value of ~20 µM. 
Quercetin-3-O-glucuronide and quercetin-7-O-glucuronide did not significantly inhibit 
sulfation even at 40 µM. Since quercetin-3-O-glucuronide, quercetin-7-O-glucuronide and 
quercetin-3′-O-sulfate all inhibited sulfation in liver S9 incubations, we propose that it is the 
uptake of quercetin conjugates that limits their inhibitory activity. Indeed, we found that the 
uptake of quercetin-3′-O-sulfate was 8-fold greater than quercetin-3-O-glucuronide and 
quercetin-7-O-glucuronide in HepG2 cells (Figure 3). While quercetin-3-O-glucuonide and 
quercetin-7-O-glucuronide can be hydrolyzed, and re-conjugated in HepG2 cells to form 
quercetin-3′-O-sulfate [22], the rate of conversion is very low (<10 % after 48 h). Thus, the 
contribution of formed quercetin-3′-O-sulfate to cellular uptake and SULT-inhibitory effect of 
quercetin glucuronides is expected to be minimal over 4 h.  
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4. Discussion 
SULTs are important determinants of the bioavailability and bioactivity of 
hydroxycinnamic acids in humans. On the other hand, dietary flavonoids are natural inhibitors 
of SULTs. Here, using human S9 homogenates, recombinant human SULT1A1 and HepG2 
cells, we demonstrated that flavonoids are potent inhibitors of hydroxycinnamic acid sulfation.  
In the intestinal S9 homogenates, all the flavonoids tested significantly inhibited sulfation 
of hydroxycinnamic acids, with the isoflavones daidzein and genistein being the most potent 
inhibitors (Table 1). In the human small intestine, SULT1A1 and SULT1A3 are highly 
expressed and they are both highly active in the conjugation of hydroxycinnamic acids [4]. Of 
the two isozymes, SULT1A3 activity is known to be relatively resistant to inhibition by 
flavonoids [17]. Hence, SULT1A3-mediated sulfation may explain the reduced inhibitory 
effect of flavonoids in the intestinal S9 compared to the liver S9.  
Nevertheless, local concentrations of flavonoids in the gut lumen are potentially much 
higher than that in the human plasma, and thus dietary flavonoids may exert inhibitory activity 
to intestinal SULTs without being absorbed into circulation. It has been estimated that 500 mg 
of polyphenols diluted in the digestive bolus would result in concentrations up to 3 mM in the 
lumen. Daily consumption of total flavonoids varies between individuals, but can easily reach 
more than 1 g [11]. Factoring in the significant transfer of different flavonoids (40-60 %) into 
the intestinal wall as shown by several ileostomy studies [18-20], dietary intake of flavonoids 
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will result in levels in the intestinal epithelial cells sufficiently high to potently inhibit both 
SULT1A1 and SULT1A3 activity. In our previous study, we showed that intestinal SULTs 
contribute, at least in part, to sulfation of hydroxycinnamic acids in vivo [4] and it may 
represent a significant site of metabolic interaction between dietary flavonoids and 
hydroxycinnamic acids.  
The liver is an important site of hydroxycinnamic acid metabolism in humans. In vitro 
incubations with liver S9 (Table 2) homogenates showed that human liver SULTs were more 
susceptible to inhibition compared to the intestine, with IC50 values in nanomolar range for 
flavones (luteolin, apigenin), flavonols (quercetin) and isoflavones (daidzein and genistein). 
This is in good agreement with several studies which showed flavonoids are potent inhibitors 
of SULTs in human liver homogenates, in particular SULT1A1 [8, 17]. Strong inhibition of 
caffeic acid and ferulic acid sulfation was also observed with both luteolin and quercetin in 
HepG2 cells, albeit with inhibitory IC50 values in low-micromolar range (4 to 20-fold higher 
than that in liver S9). Flavonoid aglycones are thus promising inhibitors of hydroxycinnamic 
acid sulfation in the human liver. 
However, circulating levels of flavonoids are much lower than that in the gut, reaching a 
maximum of 4 µM in the plasma depending on the dose and the type of flavonoids ingested 
[21, 11]. Moreover, flavonoids such as quercetin are highly metabolized in the intestine and are 
conjugated before reaching the liver [22]. Here, we demonstrate that glucuronide and sulfate 
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conjugates of quercetin also significant inhibited sulfation in human liver S9, with IC50 values 
in the low micromolar range. In HepG2 cells, quercetin-3′-O-sulfate showed inhibitory 
activity, while the glucuronides had no effect (Figure 4). Quercetin conjugates may act as 
direct inhibitors of SULTs. Quercetin glucuronides and sulfates can also be hydrolyzed by 
β-glucuronidase and sulfatase, respectively, to release the highly potent inhibitor quercetin, 
which in turn significantly inhibits SULTs-mediated sulfation of hydroxycinnamic acids. 
However, given the low sulfatase activity in HepG2 cells [22], it is likely that quercetin 
-3′-O-sulfate act predominantly as a direct inhibitor of SULTs in these cells.  
]The lack of inhibitory activity of quercetin glucuronides could be attributed to their low 
cellular uptake compared to quercetin-3′-O-sulfate (Figure 3). Of note, the human liver express 
an array of uptake transporters that are repressed in the HepG2 cells lines, which may 
contribute to an enhanced accumulation of flavonoid conjugates in liver [23]. Hence, the 
inhibitory activities of these quercetin conjugates could be greater in the liver in vivo. The 
elimination half lives of quercetin metabolites in human studies were in the range of 10-20 
hours. The relatively long half-lives of the quercetin conjugates imply that consumption of 
quercetin-rich foods can potentially inhibit hydroxycinnamic acid metabolism in vivo over a 
significant period of time (~1 day) [24].     
This study highlights the potential of flavonoids in modulating the metabolism of 
hydroxycinnamic acids via the inhibition of SULTs (Figure 5). In humans, hydroxycinnamic 
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acids are highly sulfated by SULTs, resulting in limited bioavailability of free acids in the 
plasma. Sulfation may also impact antioxidant activity. Through potent inhibition of SULTs, 
flavonoids and their in vivo conjugates have the potential to enhance the bioavailability and 
bioefficacy of hydroxycinnamic acids. Further in vivo studies will be needed to demonstrate 
the metabolic interaction between flavonoids and hydroxycinnamic acids in humans.  
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Table 1. Inhibition of caffeic acid and ferulic acid sulfation by flavonoids in intestinal S9 
 
Flavonoids 
IC50 (µM, mean ± SD) for the inhibition of sulfation of 
Caffeic acid Ferulic acid 
Apigenin 0.96 ± 0.01 2.30 ± 0.75 
Luteolin 1.33 ± 0.59 2.95 ± 1.18 
Kaempferol 2.37 ± 1.63 3.76 ± 0.45 
Isorhamnetin 4.40 ± 0.16 4.66 ± 0.21 
Quercetin 4.15 ± 0.34 5.10 ± 0.54  
Hesperetin 3.51 ± 1.40 5.04 ± 0.49 
Genistein 0.77 ± 0.02 1.50 ± 0.84 
Daidzein 0.73 ± 0.11 2.26 ± 0.43 
(+)-Catechin 5.80 ± 1.98 7.05 ± 0.64 
(-)-Epicatechin 7.65 ± 1.09 11.6 ± 3.2 
Phloretin  0.86 ± 0.27 2.17 ± 1.67 
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Table 2. Inhibition of caffeic acid and ferulic acid sulfation by flavonoids in human liver S9  
 
Flavonoids 
IC50 (µM, mean ± SD) for the inhibition of sulfation of 
Caffeic acid Ferulic acid 
Apigenin 0.46 ± 0.02 0.90 ± 0.17 
Luteolin 0.08 ± 0.01 0.53 ± 0.01 
Kaempferol 0.84 ± 0.01 3.98 ± 1.17 
Isorhamnetin 2.05 ± 1.49 3.78 ± 0.00 
Quercetin 0.41 ± 0.02 0.64 ± 0.03 
Hesperetin 4.31 ± 0.02 5.25 ± 0.24 
Genistein 0.58 ± 0.14 1.02 ± 0.02 
Daidzein 0.60 ± 0.06 0.61 ± 0.10 
(+)-Catechin 4.16 ± 0.11 4.43 ± 0.03  
(-)-Epicatechin 7.36 ± 0.10 7.28 ± 0.56  
Phloretin  0.90 ± 0.05 1.03 ± 0.02 
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Table 3. Inhibition of caffeic acid and ferulic acid sulfation by quercetin conjugates in liver S9  
 
Conjugate 
IC50 (µM, mean ± SD) for the inhibition of sulfation of 
Caffeic acid Ferulic acid 
Quercetin-3-O-glucuronide 11.5 ± 0.2 11.3 ± 0.6 
Quercetin-7-O-glucuronide 9.56 ± 0.28 8.35 ± 0.59 
Quercetin-3′-O-sulfate 6.56 ± 0.03 6.82 ± 0.28 
 
 
 
 
 
 
 
 
 
 
Figure legends: 
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Figure 1. Inhibition of hydroxycinnamic acid sulfation by daidzein (A) and genistein (B) in 
human intestinal S9. 0.4 mg / mL intestinal S9 was pre-incubated for 15 min with daidzein, 
genistein or 0.2 % DMSO. Formation of conjugates was measured after incubation of 
hydroxycinnamic acids with intestinal S9 for 30 min.  
 
Figure 2. Inhibition of hydroxycinnamic acid sulfation by luteolin (A) and quercetin (B) in 
human liver S9. 1 mg / mL liver S9 was pre-incubated for 15 min with luteolin, quercetin or 0.2 
% DMSO. Conjugate formation was measured 30 min after the addition of hydroxycinnamic 
acids.  
 
Figure 3. (A) Effect of β-glucuronidase on the inhibitory activity of quercetin glucuronides. 1 
mg / mL liver S9 was pre-incubated with quercetin-3-O-glucuronide (Q3G) and 
quercetin-7-O-glucuronide (Q7G), alone or with saccharolactone, for 15 min. Caffeic acid was 
then added and sulfate conjugate formation was measured after 30 min. (B) Uptake of 
quercetin conjugates into HepG2 cells. Uptake was assessed incubating quercetin conjugates 
(50 μM) with HepG2 cells for 4 h. Quercetin-3′-O-sulfate: Q3′S.  
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Figure 4. Inhibitory effect of luteolin, quercetin, and quercetin conjugates on sulfation of 
caffeic acid (A) and ferulic acid (B) in HepG2 cells. Caffeic acid and ferulic acid (10 μM) were 
incubated in the presence of luteolin, quercetin or quercetin conjugates for 4 h. 
Quercetin-3-O-glucuronide: Q3G; quercetin-7-O-glucuronide: Q7G; quercetin-3′-O-sulfate: 
Q3′S.  
 
Figure 5. The potential impact of flavonoids on hydroxycinnamic acid (HCA) metabolism. In 
the intestinal tract, flavonoid aglycones are potent inhibitors of hydroxycinnamic acid 
sulfation. In the liver, flavonoid conjugates are taken up and further inhibit the sulfation of 
hydroxycinnamic acid.  
 
